The risk of malignancies in RA patients treated with biologics

Zeitschrift fur Rheumatologie

Volumn 69, Issue 9, 2010, Pages 774-779

  Askling, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological drugs; Cancer; Cohort studies; Registries; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DRUG SAFETY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; OBSERVATIONAL STUDY; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER;

ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG TOXICITY; HUMANS; INCIDENCE; NEOPLASMS; RISK ASSESSMENT;

EID: 78649672279     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-010-0639-8     Document Type: Review

References (22)

1. Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10(2):R45
2. Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692-701
3. Hellgren K, Smedby KE, Feltelius N et al (2010) Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 62(5):1252-1258
4. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25(3):409-416
5. Askling JF, Nordstrom K, Ross B et al (2010) Cancer risk with tumour necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. DOI: 10.1002/art.24941
6. Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275-2285
7. Bongartz T, Warren FC, Mines D et al (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177-1183
8. Leombruno J P, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136-1145
9. Lunt M, Watson KD, Dixon WG et al (2010) No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. DOI 10.1002/art.27660
10. Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12(1):R5
11. Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60(11):3180-3189
12. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886-2895
13. Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2757-2764
14. Askling J, Baecklund E, Granath F et al (2009) Antitumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68(5):648-653
15. Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56(5):1433-1439
16. Mariette X, Tubach F, Bagheri H et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69(2):400-408
17. Askling J (2009) group As. ANTI-TNF therapy and risk of skin cancer, data from the Swedish artis registry 1998-2006. EULAR 2009
18. Franklin J, Lunt M, Bunn D et al (2007) Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56(3):790-798
19. Raaschou P, Askling J, group As. (2008) Are cancer occurring against a background of anti-TNF particularly aggressive? ACR 2008
20. Dixon WG, Watson KD, Lunt M et al (2010) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 62(6):755-763
21. Rennard SI, Fogarty C, Kelsen S et al (2007) The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(9):926-934
22. Simard J, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. DOI: 10.1002/art.27741